Th 9 cells promote antitumor immune responses in vivo

Th9 cells are a subset of CD4+ Th cells that produce the pleiotropic cytokine IL-9. IL-9/Th9 can function as both positive and negative regulators of immune response, but the role of IL9/Th9 in tumor immunity is unknown. We examined the role of IL-9/Th9 in a model of pulmonary melanoma in mice. Lack of IL-9 enhanced tumor growth, while tumor-specific Th9 cell treatment promoted stronger antitumor responses in both prophylactic and therapeutic models. Th9 cells also elicited strong host antitumor CD8+ CTL responses by promoting Ccl20/Ccr6-dependent recruitment of DCs to the tumor tissues. Subsequent tumor antigen delivery to the draining LN resulted in CD8+ T cell priming. In agreement with this model, Ccr6 deficiency abrogated the Th9 cell–mediated antitumor response. Our data suggest a distinct role for tumor-specific Th9 cells in provoking CD8+ CTL-mediated antitumor immunity and indicate that Th9 cell–based cancer immunotherapy may be a promising therapeutic approach. Research Article

[1]  R. Clark,et al.  Robust tumor immunity to melanoma mediated by interleukin 9 , 2012, Nature Medicine.

[2]  R. Flavell,et al.  Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells , 2012, Proceedings of the National Academy of Sciences.

[3]  E. Schmitt,et al.  From interleukin‐9 to T helper 9 cells , 2012, Annals of the New York Academy of Sciences.

[4]  S. Kern,et al.  Th17 cells are long lived and retain a stem cell-like molecular signature. , 2011, Immunity.

[5]  T. Korn,et al.  Cytokines and effector T cell subsets causing autoimmune CNS disease , 2011, FEBS letters.

[6]  M. Wright,et al.  Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. , 2011, Current medicinal chemistry.

[7]  B. Nourbakhsh,et al.  IL‐9 is important for T‐cell activation and differentiation in autoimmune inflammation of the central nervous system , 2011, European journal of immunology.

[8]  J. Snick,et al.  Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses , 2011, Cancer Immunology, Immunotherapy.

[9]  J. Xiang,et al.  Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity , 2011, Cancer Immunology, Immunotherapy.

[10]  Guobin Wang,et al.  Th17 cells in cancer: help or hindrance? , 2011, Carcinogenesis.

[11]  A. Coyle,et al.  IL‐9 is a Th17‐derived cytokine that limits pathogenic activity in organ‐specific autoimmune disease , 2011, European journal of immunology.

[12]  Y. Iwakura,et al.  IL-9 Promotes Th17 Cell Migration into the Central Nervous System via CC Chemokine Ligand-20 Produced by Astrocytes , 2011, The Journal of Immunology.

[13]  M. Kaplan,et al.  Regulating Il9 transcription in T helper cells. , 2011, Trends in immunology.

[14]  Mark H. Kaplan,et al.  A Brief History of IL-9 , 2011, The Journal of Immunology.

[15]  G. Mayer,et al.  IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression , 2011, The Journal of Immunology.

[16]  E. Wawrousek,et al.  Antigen-Specific Th9 Cells Exhibit Uniqueness in Their Kinetics of Cytokine Production and Short Retention at the Inflammatory Site , 2010, The Journal of Immunology.

[17]  R. Noelle,et al.  Cellular sources and immune functions of interleukin-9 , 2010, Nature Reviews Immunology.

[18]  X. Chen,et al.  Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. , 2010, Lung cancer.

[19]  Hongmei Li,et al.  IL-9: Basic Biology, Signaling Pathways in CD4+ T Cells and Implications for Autoimmunity , 2010, Journal of Neuroimmune Pharmacology.

[20]  S. Muro,et al.  IL-9 Induces CCL11 Expression via STAT3 Signalling in Human Airway Smooth Muscle Cells , 2010, PloS one.

[21]  V. Kuchroo,et al.  Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes1 , 2009, The Journal of Immunology.

[22]  P. Hwu,et al.  T helper 17 cells promote cytotoxic T cell activation in tumor immunity. , 2009, Immunity.

[23]  J. Renauld,et al.  IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[24]  B. Becher,et al.  IL-9 as a mediator of Th17-driven inflammatory disease , 2009, The Journal of experimental medicine.

[25]  P. Soroosh,et al.  Th9 and allergic disease , 2009, Immunology.

[26]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[27]  Chen Dong,et al.  CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells1 , 2008, The Journal of Immunology.

[28]  V. Kuchroo,et al.  IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells , 2008, Nature Immunology.

[29]  S. Quezada,et al.  Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma , 2008, The Journal of experimental medicine.

[30]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[31]  Clare L. Bennett,et al.  Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells , 2008, The Journal of experimental medicine.

[32]  M. Colombo,et al.  OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection , 2008, The Journal of experimental medicine.

[33]  P. Hopewell,et al.  IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. , 2008, Clinical immunology.

[34]  T. Gajewski.  Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.

[35]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[36]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[37]  M. Zanetti,et al.  CD4 T cells in tumor immunity , 2005, Springer Seminars in Immunopathology.

[38]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[39]  J. Renauld,et al.  IL-9 and its Receptor: From Signal Transduction to Tumorigenesis , 2004, Growth factors.

[40]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[41]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[42]  J. Shannon,et al.  Maintenance of the mouse type II cell phenotype in vitro. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[43]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[44]  R. Kühn,et al.  IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. , 1994, Journal of immunology.

[45]  M. Röllinghoff,et al.  Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. , 1993, Immunobiology.

[46]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[47]  A. Ohta,et al.  The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.